COMPASS Pathways (NASDAQ:CMPS) Rating Reiterated by Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports.

A number of other equities research analysts also recently commented on CMPS. HC Wainwright restated a “buy” rating and issued a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, March 1st. Morgan Stanley initiated coverage on COMPASS Pathways in a research report on Monday, April 1st. They issued an “overweight” rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $47.40.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS traded up $0.05 during midday trading on Tuesday, reaching $8.16. 34,592 shares of the company were exchanged, compared to its average volume of 675,571. The stock has a fifty day simple moving average of $9.63 and a 200 day simple moving average of $8.45. COMPASS Pathways has a 1 year low of $5.01 and a 1 year high of $12.75. The stock has a market cap of $505.43 million, a P/E ratio of -3.41 and a beta of 2.48. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.14.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, research analysts forecast that COMPASS Pathways will post -2.4 earnings per share for the current fiscal year.

Insider Transactions at COMPASS Pathways

In other COMPASS Pathways news, major shareholder George Jay Goldsmith sold 23,881 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the transaction, the insider now directly owns 3,986,523 shares in the company, valued at approximately $34,005,041.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder George Jay Goldsmith sold 23,881 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the sale, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ekaterina Malievskaia sold 25,750 shares of the company’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total value of $222,737.50. Following the completion of the transaction, the insider now owns 4,036,154 shares of the company’s stock, valued at $34,912,732.10. The disclosure for this sale can be found here. Insiders sold a total of 140,601 shares of company stock valued at $1,338,911 over the last three months. 4.25% of the stock is currently owned by insiders.

Institutional Trading of COMPASS Pathways

Institutional investors have recently made changes to their positions in the stock. PFM Health Sciences LP boosted its holdings in COMPASS Pathways by 540.7% in the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock valued at $2,964,000 after acquiring an additional 285,890 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of COMPASS Pathways in the 4th quarter valued at about $4,812,000. Quest Partners LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth about $33,000. Jump Financial LLC acquired a new stake in COMPASS Pathways during the 4th quarter worth approximately $371,000. Finally, EWA LLC acquired a new stake in COMPASS Pathways during the 4th quarter worth approximately $107,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.